Clinical trial · Interventional
Broadening the Reach, Impact, and Delivery of Genetic Services
NCT03985852CI-TRIAL-00095504BRIDGEcompletedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare the uptake of genetic testing among patients randomized with two different models of genetic services delivery (a patient-directed model and an enhanced standard of care model) and examine whether the impact on uptake differs by race/ethnicity and rurality. This study will also compare the effect of these delivery models on adherence to cancer prevention and screening recommendations and other patient responses.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Risk Reduction Behavior | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient Directed Standard of Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Patient Directed Standard of Care
- description
- Patients receive pre-test genetic counseling and, if relevant, post-test counseling for a negative result from an automated genetics education assistant.
- interventionNames
- Other: Patient Directed Standard of Care
- type
- NO_INTERVENTION
- label
- Enhanced Standard of Care
- description
- Patients receive standard counseling from a genetic counselor.
Primary outcomes (1)
- measure
- Completion of Genetic Testing From Electronic Health Record
- timeFrame
- 1 month following pre-test genetic counseling
- description
- Percentage of patients who decide to receive genetic testing
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Speaks English or Spanish AND * First degree relative or second degree relative diagnosed with the following regardless of age: Ovarian Cancer, Pancreas Cancer OR * First degree relative or second degree relative diagnosed with the following \<50 years of age: Breast Cancer, Colorectal Cancer, Endometrial Cancer. OR * Three of more relatives on the same side of the family diagnosed with the following clusters of cancer regardless of age: * Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer * Colorectal Cancer, Endometrial Cancer, Ovarian Cancer, Pancreas Cancer, Urinary tract, Brain, Small intestine * Melanoma, Pancreas Cancer OR * Ashkenazi Jewish ancestry and family history of Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer. Exclusion Criteria: * Patients with a prior cancer diagnosis, other than non-melanoma skin cancer, and/or prior genetic counseling or testing related to hereditary cancer. * Patients unable to access the patient portal
References
Publications (3)
- DERIVEDBather JR, Goodman MS, Harris A, Del Fiol G, Hess R, Wetter DW, Chavez-Yenter D, Zhong L, Kaiser-Jackson L, Chambers R, Bradshaw R, Kohlmann W, Colonna S, Espinel W, Monahan R, Buys SS, Ginsburg O, Kawamoto K, Kaphingst KA; BRIDGE research team. Social vulnerability and genetic service utilization among unaffected BRIDGE trial patients with inherited cancer susceptibility. BMC Cancer. 2025 Jan 31;25(1):180. doi: 10.1186/s12885-025-13495-4. PMID 39891096
- DERIVEDKaphingst KA, Kohlmann WK, Lorenz Chambers R, Bather JR, Goodman MS, Bradshaw RL, Chavez-Yenter D, Colonna SV, Espinel WF, Everett JN, Flynn M, Gammon A, Harris A, Hess R, Kaiser-Jackson L, Lee S, Monahan R, Schiffman JD, Volkmar M, Wetter DW, Zhong L, Mann DM, Ginsburg O, Sigireddi M, Kawamoto K, Del Fiol G, Buys SS. Uptake of Cancer Genetic Services for Chatbot vs Standard-of-Care Delivery Models: The BRIDGE Randomized Clinical Trial. JAMA Netw Open. 2024 Sep 3;7(9):e2432143. doi: 10.1001/jamanetworkopen.2024.32143. PMID 39250153
- DERIVEDKaphingst KA, Kohlmann W, Chambers RL, Goodman MS, Bradshaw R, Chan PA, Chavez-Yenter D, Colonna SV, Espinel WF, Everett JN, Gammon A, Goldberg ER, Gonzalez J, Hagerty KJ, Hess R, Kehoe K, Kessler C, Kimball KE, Loomis S, Martinez TR, Monahan R, Schiffman JD, Temares D, Tobik K, Wetter DW, Mann DM, Kawamoto K, Del Fiol G, Buys SS, Ginsburg O; BRIDGE research team. Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial. BMC Health Serv Res. 2021 Jun 2;21(1):542. doi: 10.1186/s12913-021-06489-y. PMID 34078380